JP2025510096A - アムホテリシンｂの脂質被覆結晶を含むイオンチャネル補欠組成物 - Google Patents

アムホテリシンｂの脂質被覆結晶を含むイオンチャネル補欠組成物 Download PDF

Info

Publication number
JP2025510096A
JP2025510096A JP2024556375A JP2024556375A JP2025510096A JP 2025510096 A JP2025510096 A JP 2025510096A JP 2024556375 A JP2024556375 A JP 2024556375A JP 2024556375 A JP2024556375 A JP 2024556375A JP 2025510096 A JP2025510096 A JP 2025510096A
Authority
JP
Japan
Prior art keywords
amb
pharmaceutical composition
chol
abci
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510096A5 (enExample
Inventor
ディー バーク，マーティン
レヴァンドフスカ，アグニツカ
スーター，コリン
ジー ウィアーズ，ジェフリー
タララ，トーマス
ピー ミラー，ダンフォース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Cystetic Medicines Inc
Original Assignee
University of Illinois System
Cystetic Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System, Cystetic Medicines Inc filed Critical University of Illinois System
Publication of JP2025510096A publication Critical patent/JP2025510096A/ja
Publication of JP2025510096A5 publication Critical patent/JP2025510096A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024556375A 2022-03-21 2023-03-21 アムホテリシンｂの脂質被覆結晶を含むイオンチャネル補欠組成物 Pending JP2025510096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263321965P 2022-03-21 2022-03-21
US63/321,965 2022-03-21
PCT/US2023/015762 WO2023183297A1 (en) 2022-03-21 2023-03-21 Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b

Publications (2)

Publication Number Publication Date
JP2025510096A true JP2025510096A (ja) 2025-04-14
JP2025510096A5 JP2025510096A5 (enExample) 2026-03-26

Family

ID=88101847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556375A Pending JP2025510096A (ja) 2022-03-21 2023-03-21 アムホテリシンｂの脂質被覆結晶を含むイオンチャネル補欠組成物

Country Status (12)

Country Link
US (1) US12419899B2 (enExample)
EP (1) EP4496588A4 (enExample)
JP (1) JP2025510096A (enExample)
KR (1) KR20240164801A (enExample)
CN (1) CN119365218A (enExample)
AU (1) AU2023238751A1 (enExample)
CA (1) CA3250825A1 (enExample)
CL (1) CL2024002812A1 (enExample)
CO (1) CO2024013912A2 (enExample)
IL (1) IL315719A (enExample)
MX (1) MX2024011449A (enExample)
WO (1) WO2023183297A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315719A (en) 2022-03-21 2024-11-01 Univ Illinois Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals
WO2025064626A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
CA2194049A1 (en) 1994-06-28 1996-01-11 Georgi Stankov Novel clinical uses of polyene macrolides
US6323191B1 (en) 1998-06-19 2001-11-27 Genzyme Corporation Small molecule chloride transport
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20040156792A1 (en) 2002-12-31 2004-08-12 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent
PT1581236E (pt) 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
JP2006513235A (ja) 2002-12-31 2006-04-20 ネクター セラピューティクス 真菌感染症療法のためのエアゾール化可能な医薬製剤
WO2004091572A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
ATE476965T1 (de) 2004-06-11 2010-08-15 Verma Jitendra Nath Sterol-angereicherte multilamellare amphotericin- enthaltende liposomen in kochsalzlösung und herstellungsverfahren
EP3067047B1 (en) * 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
EP2488160B1 (en) 2009-10-16 2020-07-01 Lifecare Innovations Pvt. Ltd. Liposomal amphotericin formulation comprising cholesterol for treating fungal infections
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20150297725A1 (en) * 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
KR102548341B1 (ko) 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
JP6796581B2 (ja) 2014-11-04 2020-12-09 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
EP3439668B1 (en) 2016-04-08 2024-06-19 The Board of Trustees of the University of Illinois Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia
EP3442512A4 (en) 2016-04-15 2020-07-22 The UAB Research Foundation METHODS AND COMPOUNDS FOR STIMULATING THE TRANSLECTURE OF PREMATURE TERMINATION CODONS
FI3694526T3 (fi) * 2017-10-11 2025-02-06 Univ Illinois Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten
IL315719A (en) 2022-03-21 2024-11-01 Univ Illinois Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals

Also Published As

Publication number Publication date
KR20240164801A (ko) 2024-11-20
CN119365218A (zh) 2025-01-24
EP4496588A4 (en) 2026-04-22
AU2023238751A1 (en) 2024-10-31
WO2023183297A1 (en) 2023-09-28
CL2024002812A1 (es) 2025-01-10
US12419899B2 (en) 2025-09-23
IL315719A (en) 2024-11-01
CA3250825A1 (en) 2023-09-28
CO2024013912A2 (es) 2025-01-13
MX2024011449A (es) 2024-12-06
US20250009776A1 (en) 2025-01-09
EP4496588A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
KR101621986B1 (ko) 플루오로퀴놀론의 폐 전달
JP5952231B2 (ja) ドラッグ・デリバリー用の安定な金属イオン−脂質粉末状医薬組成物とその利用方法
TW202011941A (zh) 用於治療肺部疾病的可吸入的緩釋組成物
JP2018048150A (ja) 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系
US12419899B2 (en) Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin B
CN111249260A (zh) 包含rpl554的液体吸入制剂
JP2009532489A (ja) 薬剤微粒子
US20040184995A1 (en) Novel dry powder inhalation for lung-delivery and manufacturing method thereof
AU2024345688A1 (en) Use of a dry powder inhaler to treat or prevent pulmonary fungal infections
WO2025064626A1 (en) Additive effects for molecular prosthetcs and cftr modulators in cf epithelia
AU2021200396A1 (en) Pharmaceutical composition containing budesonide and formoterol
TW202519239A (zh) 利用遺失蛋白質（ｍｉｓｓｉｎｇ ｐｒｏｔｅｉｎｓ）之小分子模擬物恢復生理機能
AU2006236049A1 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260317